Bioengineered skin and soft tissue substitutes are generally derived from autologous or allogeneic human tissue, xenographic tissue, synthetic materials, or a composite. These products are being used and evaluated for treating a variety of conditions, such as breast reconstruction, thermal injury treatment, plastic surgeries, lower extremity ulcers, and others. Bioengineered and soft tissue substitutes can either be acellular or cellular. Acellular dermal matrix (ADM) contains a scaffold or matrix of materials like hyaluronic acid, collagen, and fibronectin. ADM products can be based on species sources, additives, hydration, tissue source, and preparation mode. Cellular products incorporate living cells, such as keratinocytes and fibroblasts, embedded in a matrix. The such cellular matter could be allogeneic, autologous, or even derived from another species. Skin substitutes are usually composed of epidermal cells, dermal cells, or a combination of both and provide growth factors.
Non-healing wounds are a chief application area of bioengineered skin and skin substitute products. This area potentially included diabetic ulcers, pressure ulcers, and vascular insufficiency ulcers. Such wounds do not adequately heal with conventional wound care and may lead to prolonged morbidity and an augmented risk of mortality. Bioengineered skin substitutes have the potential to improve healing rates in such treatments in a shorter amount of time and reduce the risk of complications. Second- and third-degree burns can also be effectively treated with bioactive skin and skin substitutes.
The global market for bioengineered skin and skin substitutes is segmented on the following bases:
- Acellular dermal matrix
- Amniotic membrane
- Collagen scaffold
- Living cell therapy
- Biosynthetic products
- North America
- Rest of Europe
- Rest of Asia-Pacific
- Latin America
- Rest of Latin America
- Middle East and Africa
- GCC Countries
- South Africa
- Rest of Middle East and Africa
Key players identified for the bioengineered skin and skin substitutes market include, but are not limited to:
LifeCell Corp., Bard Davol, Ethicon, LifeNet Health, Synthes, Tissue Regenix Wound Care, KCI, TEI Biosciences, Covidien plc, MiMedix, BioD, NuTech Medical, AlloSource, Medline Industries, Cook Biotech, Organogenesis, Shire Regenerative Medicine, Genzyme Biosurgery, Soluble Systems, Forticell Bioscience, Smith & Nephew, Integra LifeSciences, Advanced Tissue Sciences, and several others.
This report offers the following:
- An overview of the global markets for bioengineered skin and skin substitutes
- Market trends assessment for the period 2013-2023, with historical information for 2013 and 2014 and projections through 2023, with respective CAGRs during 2016 and 2023
- Qualitative assessment tools such as market drivers, challenges, future prospects, major commercial events, etc.
- Market competition scrutiny tools such as market share analysis, an attractive investment proposition, and Porter’s Five Forces model
- Focus on each level of market segmentation based on product approvals, launches, and current and anticipated market dynamics.
- A general overview of the industry structure
- Company profiles highlight key information about the major players operating in the bioengineered skin and skin substitutes market.